Faro raises $37M Series B to trim clinical trial timelines with AI
What's the deal? FaroDealroom has a profile for this one. Try Dealroom → has raised a $37 million Series B round to develop AI tools aimed at speeding up clinical trials. The startup wants to address the long, costly slog of testing drugs in patients — a stage that comes after a molecule is designed.
Why now? Countless startups are already using AI to design molecules faster and cheaper. Far fewer are targeting what comes next: the clinical trial process, where Faro sees an opening.
What's the endgame? Faro is betting AI can compress trial timelines, potentially in half. Shorter trials could cut development costs and get treatments to patients sooner.
The signal: The round reflects investor appetite for AI applied beyond drug discovery and into the messier, more expensive work of clinical development — a bottleneck the wider biopharma sector has yet to crack.
Read more: endpoints.news
Image credit: Generated with Gemini
